Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
|Videos|June 21, 2019
FGFR Inhibition: A Novel Therapeutic Strategy
General Cancer
Advertisement
Advertisement
Related to this article
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.
Advertisement
Advertisement
Trending on Targeted Onc
1
Lonardi on Overall Survival With Nivolumab/Ipilimumab in MSI-H/dMMR mCRC
2
JNJ-6143 Elicits PSA Responses in Heavily Pretreated mCRPC
3
BMI Limitations Complicate Obesity and Cancer Research
4
Geron Halts Phase 3 Imetelstat Trial in Relapsed/Refractory Myelofibrosis
5